Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose IL-2 for Active Dermatomyositis
NCT05495321Phase 3Enrolling by invitation
- Sponsor
- Peking University People's Hospital
- Start
- Dec 2022
- Primary completion
- Sep 2025
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dermatomyositis (DM) comparing Low-dose IL-2 with Placebo (2 arms). Primary endpoint: Total Improvement Score Response at 12 weeks. Started Dec 2022; status: enrolling by invitation.
02
Drugs
aldesleukin
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on NCT05495321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05495321.